Tesamorelin
Also known as: TH 9507 · tesamorelina · tesamoreline · tesamorelinum
Tesamorelin is a growth-hormone-releasing hormone (GHRH) analog and an FDA-approved prescription drug marketed as Egrifta. Research-grade tesamorelin is distinct from the approved pharmaceutical and is studied primarily for its effects on visceral fat reduction and growth hormone stimulation in preclinical and clinical investigations.
What is Tesamorelin?
Tesamorelin is a synthetic peptide drug classified as a growth-hormone-releasing hormone (GHRH) analog. It was developed to mimic the endogenous hypothalamic hormone responsible for stimulating the pituitary gland to produce growth hormone. This peptide is structurally designed to be more stable and longer-acting than native GHRH, enhancing its pharmacological profile for research and therapeutic purposes.
Originally created to address conditions related to growth hormone deficiency and metabolic complications, tesamorelin has been extensively evaluated in clinical settings, leading to its FDA approval as a pharmaceutical agent for specific indications. However, research-grade tesamorelin is distinct from the approved drug formulation and is utilized in laboratory and experimental contexts to explore its biological effects.
Researchers focus on tesamorelin due to its capacity to increase endogenous growth hormone secretion, which in turn activates insulin-like growth factor 1 (IGF-1) signaling pathways. These pathways play critical roles in tissue repair, cellular regeneration, and metabolic regulation. Current research explores its potential applications in metabolic diseases, fat distribution modulation, and regenerative medicine.
As a peptide with a molecular weight of approximately 5136 g/mol and a complex amino acid sequence, tesamorelin is of interest in peptide pharmacology and endocrinology research, where understanding growth hormone axis modulation remains a significant area of investigation.
Key Benefits & Mechanisms
- Visceral Fat ReductionPreclinical and clinical studies have investigated tesamorelin’s ability to reduce visceral adipose tissue. By stimulating growth hormone release, tesamorelin influences lipid metabolism and fat redistribution, which may offer benefits in conditions characterized by abnormal fat accumulation, such as lipodystrophy and metabolic syndrome. Research continues to examine the mechanisms underlying these effects and their potential therapeutic relevance.
- Stimulation of Growth Hormone and IGF-1 PathwaysTesamorelin acts on the growth hormone-releasing hormone receptor to increase endogenous growth hormone secretion, subsequently elevating circulating levels of insulin-like growth factor 1 (IGF-1). This cascade is involved in multiple physiological processes including anabolic effects on muscle, enhancement of cellular repair mechanisms, and promotion of tissue regeneration, making it a molecule of interest in regenerative medicine research.
- Potential Role in Tissue Repair and RegenerationThrough activation of IGF-1 signaling pathways, tesamorelin may contribute to cellular regeneration and repair processes. Research peptides with growth hormone secretagogue activity, including tesamorelin, are being evaluated for their capacity to support recovery from musculoskeletal injuries by modulating satellite cell activation and promoting anabolic signaling within damaged tissues.
- Metabolic RegulationTesamorelin’s influence on the growth hormone axis also impacts glucose metabolism and lipid profiles. Although the precise metabolic effects continue to be studied, initial research suggests that tesamorelin may modulate insulin sensitivity and energy homeostasis, which are relevant factors in the context of metabolic disorders and obesity-related complications.
Mechanism of action
Tesamorelin functions as a growth hormone secretagogue by selectively binding to and activating the growth hormone-releasing hormone (GHRH) receptor located on pituitary somatotroph cells. This receptor activation triggers intracellular signaling cascades that stimulate the synthesis and pulsatile release of endogenous growth hormone. The increased growth hormone levels then stimulate the production and release of insulin-like growth factor 1 (IGF-1) primarily from the liver. IGF-1 acts in an endocrine and paracrine fashion to promote anabolic effects, including cellular proliferation, differentiation, and tissue repair. This mechanism links tesamorelin’s action to key regenerative and metabolic pathways, highlighting its potential utility as a research tool in studying growth hormone axis modulation and its downstream biological effects.
Research Summary
Tesamorelin has been investigated in the context of orthopaedic and regenerative medicine research, as summarized in recent literature. The 2026 review titled "Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions" highlights the role of growth hormone secretagogues, including tesamorelin, in activating IGF-1 signaling and satellite cell repair pathways relevant to tissue regeneration and recovery. This review underscores the promise of peptides like tesamorelin to influence musculoskeletal healing processes, while noting the current paucity of clinical trial data.
The article "Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians" (2026) discusses the expanding interest in peptides such as tesamorelin for regenerative applications and sports medicine. It emphasizes the need for orthopaedic clinicians to understand the biochemical and preclinical evidence supporting peptide therapies. Tesamorelin is mentioned alongside other growth hormone secretagogues for its potential to enhance tissue repair by stimulating IGF-1 pathways. However, it also notes that clinical validation remains limited and further research is necessary to establish efficacy and safety profiles.
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. (2026) PubMed · PMID 41490200
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. (2026) PubMed · PMID 41476424
Dosing in Research Literature
Research literature on tesamorelin includes various dosing regimens primarily in clinical trial settings, often involving daily subcutaneous injections. The specific dose ranges employed in these studies vary, reflecting different research objectives such as metabolic modulation or fat reduction. However, precise dosing protocols for laboratory or preclinical use are not consistently established in the literature.
In preclinical studies, tesamorelin dosing is generally designed to achieve pharmacologically relevant stimulation of growth hormone secretion without inducing adverse effects. Researchers often tailor dosing according to experimental models and endpoints, with careful consideration of pharmacokinetics and peptide stability. Due to the variability and lack of standardized dosing guidelines, detailed dose ranges should be referenced directly from individual research publications.
The figures above describe doses reported in published or preclinical research, provided for context only. This is not medical advice or a dosing recommendation, and these compounds are not approved for human use.
Common Stacks
Frequently asked questions about Tesamorelin
What is tesamorelin and what is its FDA approval status?
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) that stimulates endogenous growth hormone secretion. It is FDA-approved as a prescription drug marketed under the name Egrifta for specific medical indications related to fat accumulation disorders. Research-grade tesamorelin is distinct from the approved pharmaceutical formulation and is used solely for laboratory and experimental purposes.
For what research purposes is tesamorelin primarily studied?
Tesamorelin is primarily studied for its ability to stimulate growth hormone and insulin-like growth factor 1 (IGF-1) pathways, which are implicated in fat metabolism, tissue repair, and cellular regeneration. Research focuses include investigating its effects on visceral fat reduction, metabolic regulation, and potential applications in musculoskeletal and regenerative medicine.
How does tesamorelin exert its biological effects at the molecular level?
Tesamorelin binds to the growth hormone-releasing hormone (GHRH) receptor on pituitary cells, triggering growth hormone secretion. The increased growth hormone then promotes IGF-1 release, which facilitates anabolic and regenerative processes in various tissues. This mechanism positions tesamorelin as a growth hormone secretagogue influencing metabolic and repair pathways.
Can tesamorelin be combined with other peptides, and why is this investigated?
Yes, tesamorelin is studied in combination with other peptides such as CJC-1295, ipamorelin, and GHRP-2. These combinations are researched to potentially enhance and prolong growth hormone release through complementary mechanisms, aiming to amplify anabolic and regenerative effects in preclinical models.
What considerations are important for the storage and handling of research-grade tesamorelin?
Research-grade tesamorelin, like many peptides, requires careful storage typically at low temperatures (e.g., refrigerated or frozen) to maintain stability and bioactivity. It should be handled under sterile conditions to prevent degradation or contamination. Researchers should refer to manufacturer guidelines for specific storage recommendations and ensure proper reconstitution protocols are followed for experimental use.
Legal & research status: Tesamorelin is an FDA-approved prescription drug (marketed as Egrifta). Material sold as a research peptide is not the approved pharmaceutical product and is offered for laboratory and research use only, not for human consumption.